The global bipolar disorder market size is estimated to value USD 5.56 billion by 2026 from USD 5 billion in 2021, growing at a CAGR of 2.12% from 2021 to 2026. The bipolar disorder market is growing at a slow yet constant pace. Advancements in technology allowing the detection of a patient’s mood with more accuracy positively influence market growth. The government’s Bipolar Disorder awareness campaigns also propel market growth.
Bipolar disorder is formerly known as manic depression. It is a type of mental illness specified by pathological mood swings from mania to depression. Bipolar depression is a mental disorder whose symptoms include periods with mood swings of severe depression or emotional highs. It was once called Manic Depression. In recent years, the general public awareness of the symptoms and treatment of Bipolar Disorder is on the rise. Typically, the treatment for bipolar disorder is for a lifetime. An abnormally elevated mood that lasts for days to each depends on the individual. The sudden changes in the mental state bring out high or low spirits in a person. During mania, an individual behaves or feels abnormally happy, energetic, and irritable. They often make impulsive decisions with little regard for the consequences; there is also a reduced need for sleep during maniac phases. According to the Institute for Health Matric and Evaluation (IHME), it is estimated that the presence of bipolar disorder across the world is varied by country from 0.3 to 1.2%. With 52% to 48% being male and female globally, forty-six million people had bipolar in 2017.
MARKET DRIVERS:
The rise in the prevalence of bipolar disorder and the various risks such as high stress, substance abuse, and others and advancements in a combination of drugs, and the need for antidepressant medications are primarily propelling the global bipolar disorder market growth. The other factors such as increasing research and development activities and investments by the government to improve the healthcare industry are expected to drive the market growth.
Moreover, creating awareness among the people about bipolar disorder and the advanced technologies that facilitate precise detection of a patient mood and mental state are further accelerating the growth of the bipolar disorder market.
MARKET RESTRAINTS:
The key restraints on the market growth come from the inadequate facilities for the diagnosis of bipolar disorder. Strict government rules on misdiagnosis of the disorder and insufficient equipment result in bipolar disorder being written off as just another personality disorder or depression. Several of the drugs used in the treatment of the disorder have been found to have addictive side-effects, resulting in controlled manufacturing of the required pharmaceuticals. The use of tricyclic antidepressants has been declined due to a higher incidence of side effects than other drugs used in bipolar disorder treatment.
Impact of covid-19 on the global bipolar disorder market:
COVID-19 was announced as a pandemic and emergence of healthcare by World Health Organization. The governments had imposed nationwide lockdown to stop the widespread of the coronavirus. COVID 19 has affected every individual directly or indirectly. Doctors took special care of the patients who have long-term mental illness as the COVID 19 shows adverse symptoms. People with the mentally ill are especially affected by the COVID 19 as it triggers the severe illness. Hence, the demand for the bipolar disorder market has an inclined growth rate during this period.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Type, Mechanism of Action, Drug Class and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc and AbbVie, Inc. |
This research report on the global bipolar disorder market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2026.
Bipolar Disorder Market – By Type:
Based on the type. The bipolar I disorder segment is leading with the dominant shares in the global bipolar disorder market. Increasing incidences of chronic illness among people with growing stress levels is a major factor for holding the highest shares. THE Bipolar II disorders segment is positioned second in leading with the highest shares of the market.
Bipolar Disorder Market – By Mechanism of Action:
Based on the mechanism of action, the market is predicted to be led by Serotonin-norepinephrine reuptake inhibitors until 2019 due to their safety in treating major depression. Serotonin-norepinephrine Reuptake Inhibitors are a class of medications that are effective in treating depression.
Bipolar Disorder Market – By Drug Class:
The rising occurrence of depression stemming from physical illness and psychosis resulted in Antipsychotic drugs leading this market segment based on drug class. Increasing occurrence of depression stemming from physical illness and psychosis resulted in antipsychotic medications, which are the leading segment in the market. These Antidepressants are medications used to treat a major depressive disorder, some anxiety disorders, and some chronic pain conditions.
Bipolar Disorder Market – By Region:
Geographically, the global bipolar disorder market is expected to be led by North America, resulting from high levels of stress and wide substance abuse issues. Various government schemes and campaigns designed to create awareness fuel the expansion of the market in Europe and North America.
In 2019, over 50% of the global bipolar disorder market was accounted for by the North American region and forecasted during the forecast period; this region shows its dominance. Y-O-Y growth in the prevalence of the bipolar disorder in this region is majorly increasing the market demand. A considerable amount of the North American region population is suffering from high stress and sleep issues, which is increasing the incidence of bipolar disorder in this region and driving this regional market growth. Governments of North American countries have initiated various programs to increase the awareness about bipolar disorder among the population in recent times, which is further estimated to favor the market growth.
Among the other regions, the Asia Pacific market is forecasted to exhibit a brisk pace during the forecast period. The incidence of mental disorders is significantly growing in APAC countries such as India and China in the recent past. Hence, this factor is expected to accelerate the treatment market for bipolar disorder in this region during the forecast period.
KEY MARKET PLAYERS:
Companies that are playing a promising role in the Global Bipolar Disorder Market profiled in this report are Gedeon Richter, Indivior, AstraZeneca, Janssen Pharmaceuticals, Lundbeck, Bristol-Myers Squibb, Ostuca Holdings Co. Ltd., Glaxo SmithKline (GSK), Allergan Plc, Pfizer, Inc. and AbbVie, Inc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Method
5.1.1 Introduction
5.1.2 Genotypic
5.1.3 Proteomics-based
5.1.4 Phenotypic
5.1.5 Y-o-Y Growth Analysis, By Method
5.1.6 Market Attractiveness Analysis, By Method
5.1.7 Market Share Analysis, By Method
5.2 Application
5.2.1 Introduction
5.2.2 F&B
5.2.3 Diagnostic
5.2.4 Pharmaceutical
5.2.5 Environmental
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 Product
5.3.1 Introduction
5.3.2 Identification Services
5.3.3 Consumables
5.3.4 Instruments
5.3.5 Y-o-Y Growth Analysis, By Products and Services
5.3.6 Market Attractiveness Analysis, By Products and Services
5.3.7 Market Share Analysis, By Products and Services
5.4 End User
5.4.1 Food Manufacturing Industries
5.4.2 Pharmaceutical Companies
5.4.3 Hospitals and Diagnostic Centres
5.4.4 Other End users
5.3.5 Y-o-Y Growth Analysis, By End User
5.3.6 Market Attractiveness Analysis, By End User
5.3.7 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Method
6.1.3.3 By Application
6.1.3.4 By Product
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Method
6.1.4.3 By Application
6.1.4.4 By Product
6.1.4.5 By End user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Method
6.1.5.3 By Application
6.1.5.4 By Product
6.1.5.5 By End user
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Shimadzu Corporation
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Dickinson & Company
8.3 Biolog Inc.
8.4 Merck KGaA
8.5 IEH Laboratories & Consulting Group
8.6 Trivitron Healthcare
8.7 Laboratory Corporation of America Holdings
8.8 Thermo Fisher Scientific Inc.
8.9 Bruker Corporation
8.10 Charles River Laboratories
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
